![Altana Aktiengesellschaft](/common/images/company/NY_AAA.png)
Alternative Access Funds Launches First Priority CLO Bond ETF 'AAA' PR Newswire NEW YORK, Sept. 9, 2020 NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Alternative Access Funds, LLC ("AAF") is pleased to...
- Lower dose of ciclesonide effectively controls asthma symptoms and maintains lung function MUNICH, Germany, Sept. 4 /PRNewswire-FirstCall/ -- New efficacy data was presented for the first time...
Awards Honor Companies Creating Breakthroughs in Pharmaceutical and Life Sciences Industry Through the Use of Microsoft Technology PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- Microsoft Corp...
INNSBRUCK, Austria, April 6 /PRNewswire/ -- Based on successful pilot studies in high-resolution pharmacodynamics, BIOCRATES Life Sciences GmbH and ALTANA Pharma AG signed a collaboration...
Major Milestone in Broadening the Ciclesonide Product Platform FLORHAM PARK, N.J., March 7 /PRNewswire-FirstCall/ -- ALTANA Pharma US, Inc. announced today that the U.S. Food and Drug...
Latest Findings Presented at the 2005 American College of Allergy, Asthma and Immunology Annual Meeting Also Demonstrated Alvesco Had No Effect on HPA-Axis Function ANAHEIM, Calif., Nov. 7...
Sharon O'Hara, 66, was humbled by her loss of physical strength. She realized she had reached a low point when she had to crawl on the kitchen floor to feed her dogs. O'Hara, a former smoker, had...
ALTANA Inc Inaugurates 100,000 sq. ft. of Manufacturing Space in Hicksville, New York - Leading Pharmaceutical Manufacturer Cites Growth and Increased Demand for Topical Drugs Behind Expansion...
Nanophase Technologies Announces Exclusive Partnership With and $10 Million Investment by Altana Chemie AG ROMEOVILLE, Ill., March 25 /PRNewswire-FirstCall/ -- Nanophase Technologies Corporation...
Saturday test ignore Pimswire
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.